ProQR Therapeutics receives CTA authorization for AX-0810

ProQR Therapeutics (PRQR) announced that following review under the new European Medicines Agency, EMA, centralized review process, the Central Committee on Research Involving Human Subjects, CCMO, has authorized ProQR’s Clinical Trial Application, CTA, for a Phase 1 study of AX-0810 in healthy volunteers. AX-0810 is the Company’s lead investigational editing oligonucleotide, EON, targeting NTCP, which is being developed for the treatment of cholestatic diseases like primary sclerosing cholangitis and biliary atresia.